Galmed Pharmaceuticals Ltd - Asset Resilience Ratio
Galmed Pharmaceuticals Ltd (GLMD) has an Asset Resilience Ratio of 76.08% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Galmed Pharmaceuticals Ltd debt and liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2014–2025)
This chart shows how Galmed Pharmaceuticals Ltd's Asset Resilience Ratio has changed over time. See Galmed Pharmaceuticals Ltd (GLMD) shareholders funds for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Galmed Pharmaceuticals Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Galmed Pharmaceuticals Ltd (GLMD) total market value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $14.17 Million | 76.08% |
| Total Liquid Assets | $14.17 Million | 76.08% |
Asset Resilience Insights
- Very High Liquidity: Galmed Pharmaceuticals Ltd maintains exceptional liquid asset reserves at 76.08% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Galmed Pharmaceuticals Ltd Industry Peers by Asset Resilience Ratio
Compare Galmed Pharmaceuticals Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO |
Biotechnology | 11.59% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS |
Biotechnology | 0.58% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
BioArctic AB (publ)
ST:BIOA-B |
Biotechnology | 72.35% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for Galmed Pharmaceuticals Ltd (2014–2025)
The table below shows the annual Asset Resilience Ratio data for Galmed Pharmaceuticals Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 76.08% | $14.17 Million | $18.63 Million | +18.35pp |
| 2024-12-31 | 57.72% | $10.68 Million | $18.50 Million | -1.09pp |
| 2023-12-31 | 58.82% | $9.78 Million | $16.63 Million | -12.25pp |
| 2022-12-31 | 71.06% | $11.77 Million | $16.56 Million | -16.17pp |
| 2021-12-31 | 87.23% | $31.93 Million | $36.60 Million | +3.35pp |
| 2020-12-31 | 83.88% | $43.94 Million | $52.38 Million | +6.67pp |
| 2019-12-31 | 77.21% | $59.56 Million | $77.14 Million | +4.33pp |
| 2018-12-31 | 72.88% | $66.03 Million | $90.60 Million | +42.46pp |
| 2017-12-31 | 30.42% | $5.98 Million | $19.64 Million | -44.66pp |
| 2016-12-31 | 75.08% | $12.35 Million | $16.45 Million | -2.59pp |
| 2015-12-31 | 77.67% | $18.84 Million | $24.26 Million | +52.61pp |
| 2014-12-31 | 25.06% | $8.25 Million | $32.92 Million | -- |
About Galmed Pharmaceuticals Ltd
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes me… Read more